Analysis and Evaluation of Smoking Treatment With Cytisine

Regina Elena Cancer Institute

Status: Enrolling

Conditions: Moderate or Severe Tobacco Use Disorder

Treatments: Drug: Cytisine 1,5 mg

Study type: Observational

Funder types: Other

Identifiers

NCT06439303

RS104/IRE/24

Details and patient eligibility

About

The lack of clinical studies on the use of Cytisine in the treatment of the cessation of smoking, the need to find effective therapeutic alternatives and the opportunity to reduce costs related to the complications of cigarette smoking, represent the main reasons that led to the design of this study.

Full description

The study is observational, retrospective and monocentric, and aims to evaluate patients who performed an initial pneumological examination at the Anti-Smoking Center of the National Institute Regina Elena tumors due to smoking cessation in the reference period. To such patients, affected of moderate or severe tobacco use disorder, drug therapy was prescribed with Cytisine 1.5 mg, with the aim of evaluating treatment adherence, efficacy and tolerability of Cytisine as monotherapy in the treatment of moderate or moderate tobacco use disorder serious. Responding patients will be taken into consideration for the study consecutively to the criteria established and pertaining to the Anti-Smoking Center of the National Cancer Institute Regina Elena in the period between 02/01/2023 and 11/30/2023 on first and subsequent visits controls.

Enrollment: 65 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients aged > 18 years;
• patients suffering from moderate or severe tobacco use disorder;
• prescription of pharmacological therapy with Cytisine;
• patients returned to the 1st check-up on schedule;

Exclusion criteria

• Patients with contraindications to taking Cytisine and partial receptor agonists nicotinic cholinergics;
• Patients undergoing pharmacological or physical treatment for neoplastic pathology;
• Pregnant or breastfeeding women;
• Patients for whom specific information for objective assessments is not available;

Trial design

65 participants in 1 patient group

Patients with moderate or severe tobacco use disorder.

Description:

Patients hospitalized at the IRE anti-smoking center, National Cancer Institute "Regina Elena", suffering from moderate or severe tobacco use disorder, who are prescribed pharmacological therapy with Cytisine 1.5 mg.

Treatment:

Drug: Cytisine 1,5 mg